
Zoetis (ZTS) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
2.2B
Gross Profit
1.6B
71.98%
Operating Income
846.0M
38.11%
Net Income
631.0M
28.42%
EPS (Diluted)
$1.41
Balance Sheet Metrics
Total Assets
14.1B
Total Liabilities
9.4B
Shareholders Equity
4.7B
Debt to Equity
2.03
Cash Flow Metrics
Operating Cash Flow
567.0M
Free Cash Flow
438.0M
Revenue & Profitability Trend
Zoetis Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 9.3B | 8.5B | 8.1B | 7.8B | 6.7B |
Cost of Goods Sold | 2.7B | 2.6B | 2.5B | 2.3B | 2.1B |
Gross Profit | 6.5B | 6.0B | 5.6B | 5.5B | 4.6B |
Gross Margin % | 70.6% | 70.0% | 69.6% | 70.4% | 69.2% |
Operating Expenses | |||||
Research & Development | 686.0M | 614.0M | 539.0M | 508.0M | 463.0M |
Selling, General & Administrative | 2.3B | 2.2B | 2.0B | 2.0B | 1.7B |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 3.0B | 2.8B | 2.5B | 2.5B | 2.2B |
Operating Income | 3.4B | 3.1B | 2.9B | 2.8B | 2.3B |
Operating Margin % | 36.6% | 35.9% | 36.2% | 36.0% | 34.0% |
Non-Operating Items | |||||
Interest Income | 106.0M | 105.0M | 50.0M | 6.0M | 12.0M |
Interest Expense | 225.0M | 239.0M | 221.0M | 224.0M | 231.0M |
Other Non-Operating Income | -140.0M | 1.0M | -101.0M | -97.0M | -54.0M |
Pre-tax Income | 3.1B | 2.9B | 2.7B | 2.5B | 2.0B |
Income Tax | 637.0M | 596.0M | 545.0M | 454.0M | 360.0M |
Effective Tax Rate % | 20.3% | 20.3% | 20.5% | 18.2% | 18.0% |
Net Income | 2.5B | 2.3B | 2.1B | 2.0B | 1.6B |
Net Margin % | 27.0% | 27.4% | 26.1% | 26.2% | 24.5% |
Key Metrics | |||||
EBITDA | 4.0B | 3.7B | 3.5B | 3.3B | 2.7B |
EPS (Basic) | $5.47 | $5.08 | $4.51 | $4.29 | $3.44 |
EPS (Diluted) | $5.47 | $5.07 | $4.49 | $4.27 | $3.42 |
Basic Shares Outstanding | 454200000 | 461172000 | 468900000 | 474300000 | 475502000 |
Diluted Shares Outstanding | 454200000 | 461172000 | 468900000 | 474300000 | 475502000 |
Income Statement Trend
Zoetis Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 2.0B | 2.0B | 3.6B | 3.5B | 3.6B |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 1.3B | 1.3B | 1.2B | 1.1B | 1.0B |
Inventory | 2.3B | 2.6B | 2.3B | 1.9B | 1.6B |
Other Current Assets | 377.0M | 434.0M | 365.0M | 389.0M | 366.0M |
Total Current Assets | 6.0B | 6.3B | 7.5B | 6.9B | 6.6B |
Non-Current Assets | |||||
Property, Plant & Equipment | 219.0M | 230.0M | 220.0M | 181.0M | 192.0M |
Goodwill | 6.6B | 6.9B | 6.9B | 6.8B | 7.1B |
Intangible Assets | 1.1B | 1.3B | 1.4B | 1.5B | 1.7B |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 790.0M | 412.0M | 320.0M | 211.0M | 200.0M |
Total Non-Current Assets | 8.3B | 7.9B | 7.4B | 7.0B | 7.0B |
Total Assets | 14.2B | 14.3B | 14.9B | 13.9B | 13.6B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 433.0M | 411.0M | 405.0M | 436.0M | 457.0M |
Short-term Debt | 1.4B | 3.0M | 1.4B | - | 604.0M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 125.0M | 102.0M | 97.0M | 67.0M | 93.0M |
Total Current Liabilities | 3.4B | 1.9B | 3.2B | 1.8B | 2.2B |
Non-Current Liabilities | |||||
Long-term Debt | 5.4B | 6.8B | 6.7B | 6.7B | 6.8B |
Deferred Tax Liabilities | 167.0M | 146.0M | 142.0M | 320.0M | 378.0M |
Other Non-Current Liabilities | 222.0M | 237.0M | 217.0M | 239.0M | 270.0M |
Total Non-Current Liabilities | 6.1B | 7.4B | 7.4B | 7.6B | 7.7B |
Total Liabilities | 9.5B | 9.3B | 10.5B | 9.4B | 9.8B |
Equity | |||||
Common Stock | 5.0M | 5.0M | 5.0M | 5.0M | 5.0M |
Retained Earnings | 12.0B | 10.3B | 8.7B | 7.2B | 5.7B |
Treasury Stock | 7.4B | 5.6B | 4.5B | 3.0B | 2.2B |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 4.8B | 5.0B | 4.4B | 4.5B | 3.8B |
Key Metrics | |||||
Total Debt | 6.7B | 6.8B | 8.1B | 6.7B | 7.4B |
Working Capital | 2.6B | 4.5B | 4.3B | 5.1B | 4.4B |
Balance Sheet Composition
Zoetis Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 2.5B | 2.3B | 2.1B | 2.0B | 1.6B |
Depreciation & Amortization | 497.0M | 491.0M | 465.0M | 448.0M | 441.0M |
Stock-Based Compensation | 74.0M | 60.0M | 62.0M | 58.0M | 59.0M |
Working Capital Changes | 79.0M | -512.0M | -699.0M | -343.0M | -85.0M |
Operating Cash Flow | 2.8B | 2.3B | 1.7B | 2.1B | 2.0B |
Investing Activities | |||||
Capital Expenditures | - | - | - | - | - |
Acquisitions | 285.0M | -59.0M | -312.0M | -14.0M | -113.0M |
Investment Purchases | -5.0M | -4.0M | -9.0M | -12.0M | -27.0M |
Investment Sales | 62.0M | 12.0M | 23.0M | 44.0M | 0 |
Investing Cash Flow | 340.0M | -45.0M | -297.0M | 19.0M | -119.0M |
Financing Activities | |||||
Share Repurchases | -1.9B | -1.1B | -1.6B | -743.0M | -250.0M |
Dividends Paid | -786.0M | -692.0M | -611.0M | -474.0M | -380.0M |
Debt Issuance | 0 | 0 | 1.3B | 0 | 1.2B |
Debt Repayment | 0 | -1.4B | 0 | -600.0M | -500.0M |
Financing Cash Flow | -2.7B | -3.1B | -866.0M | -1.8B | 103.0M |
Free Cash Flow | 2.3B | 1.6B | 1.3B | 1.7B | 1.7B |
Net Change in Cash | 490.0M | -871.0M | 503.0M | 310.0M | 2.0B |
Cash Flow Trend
Zoetis Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
25.36
Forward P/E
23.24
Price to Book
13.14
Price to Sales
6.96
PEG Ratio
23.24
Profitability Ratios
Profit Margin
27.83%
Operating Margin
40.20%
Return on Equity
52.77%
Return on Assets
15.37%
Financial Health
Current Ratio
1.76
Debt to Equity
137.01
Beta
0.88
Per Share Data
EPS (TTM)
$5.81
Book Value per Share
$11.21
Revenue per Share
$20.90
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
zts | 65.3B | 25.36 | 13.14 | 52.77% | 27.83% | 137.01 |
Haleon Plc - ADR | 43.6B | 21.44 | 5.44 | 9.38% | 13.81% | 53.41 |
Intra-Cellular | 14.0B | -183.15 | 12.20 | -8.58% | -10.97% | 1.48 |
United Therapeutics | 13.6B | 11.76 | 1.90 | 19.30% | 40.36% | 0.00 |
Neurocrine | 13.1B | 38.94 | 4.84 | 13.39% | 13.88% | 18.18 |
Viatris | 12.5B | 235.80 | 0.80 | -19.77% | -24.57% | 94.78 |
Financial data is updated regularly. All figures are in the company's reporting currency.